APA (7th ed.) Citation
(2026). Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: An open-label extension of the phase 3 DRAGON study. Journal of Headache and Pain.
Chicago Style (17th ed.) Citation
"Long-term Safety and Continued Clinical Benefit of Erenumab 70 Mg in Asian Patients with Chronic Migraine: An Open-label Extension of the Phase 3 DRAGON Study." Journal of Headache and Pain 2026.
MLA (9th ed.) Citation
"Long-term Safety and Continued Clinical Benefit of Erenumab 70 Mg in Asian Patients with Chronic Migraine: An Open-label Extension of the Phase 3 DRAGON Study." Journal of Headache and Pain, 2026.
Warning: These citations may not always be 100% accurate.